

Cost-effectiveness of prevention:

Community-based interventions to control and prevent Lyme disease

Martin Meltzer, Ph.D., MS

Division of Preparedness & Emerging Infections (DPEI)

Centers for Disease Control and Prevention (CDC)

E-mail: qzm4@cdc.gov



Disclaimer

This presentation represents the work of the author and does not necessarily represent the policy or opinion of the CDC or DHHS.



What is . . .

**The cost-effectiveness of community-based
Lyme disease control measures?**

ANSWER:

➤ Not sure

➤ No readily accessible published studies.

➤ WHY no available answer?

➤ Missing/ non-existent data

What is cost-effectiveness?

- Expressed as \$/ per unit health outcome
 - E.g., \$/ case averted
- Cost per case =
$$\frac{\$ \text{ Intervention} - \$ \text{ saved}}{\text{Cases averted}}$$

REMEMEBR

Cost-Effectiveness \neq Cost Savings

What is:

a “reasonable” threshold?


the maximum “allowable” \$/ case averted?

“Cost-Effectiveness” is SUBJECTIVE term

FURTHER

Cost Savings \neq “Must Do”

Economics: Part of the "Decision pie"



4 data “buckets” needed for a good cost-effectiveness study

- Epidemiology and clinical
 - Who, when where, what happens
- Cost of clinical illnesses and outcomes
- Interventions
 - What, how well work, where, side effects?
 - Must have a comparator
- Cost of interventions
 - Must include \$ of treating side effects

Epidemiological data: Risk clinical case

Confirmed cases / 100,000 population


| State | 2007 | 2008 | 2009 |
|-------------------------|------|------|-------|
| Alabama | 0.3 | 0.1 | 0.1 |
| Alaska | 1.5 | 0.9 | 1.0 |
| Arizona | 0.0 | 0.0 | 0.0 |
| Arkansas | 0.0 | 0.0 | 0.0 |
| California | 0.2 | 0.2 | 0.3 |
| Colorado | 0.0 | 0.0 | 0.0 |
| Connecticut | 87.3 | 78.2 | 78.2 |
| Delaware | 82.7 | 88.4 | 111.2 |
| District of Columbia | 19.7 | 12.0 | 8.8 |
| Florida | 0.2 | 0.4 | 0.4 |
| Michigan | 0.5 | 0.8 | 0.8 |



Source: http://www.cdc.gov/ncidod/dvbid/lyme/ld_IncidenceRatesbyState20052009.htm

Epidemiological data: Risk clinical case

Reported Cases of Lyme Disease -- United States, 2009



1 dot placed randomly within county of residence for each confirmed case



Source: http://www.cdc.gov/ncidod/dvbid/lyme/ld_Incidence.htm

Epidemiological data

E P I D E M I O L O G Y A N D D E T E R M I N A N T S

GARY SMITH, DPHIL ■ E. PAUL WILEYTO, PHD MS

ROBERT B. HOPKINS ■ BRYAN R. CHERRY, VMD

JOHN P. MAHER, MD MPH

Risk Factors for Lyme Disease in Chester County, Pennsylvania

Smith et al. Public Hlth Report 2001 (supp 1).



Epidemiological data

➤ Risk factors:

- Age: 10-19 years; and 50+ years of age
- Rural > urban (3 times more)
- Single homes, homes with woods, <100 ft to woods
- Gardening + 4 hrs/ week


➤ Other factors: not risk

Source: Smith et al. Public Hlth Report 2001 (supp 1).


➤ MUST place risk in context

- Geography, season, exact activity, ecology, etc.

Reported Lyme Disease Cases by Age Category, United States, 1992-2006



Clinical Features of Lyme Disease Cases Reported to CDC, United States, 1992-2006




MMWR
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Surveillance Summaries October 3, 2008 / Vol. 57 / No. 55-56

Surveillance for Lyme Disease –
United States, 1992-2006




Change in Frequency of Clinical Features, United States, 1992-2006



Bucket #2: Cost of case


Figure 2. Trend of direct medical cost of Lyme disease 1997-2000



Note: \$ costs in 2000 \$

Source: Zhang et al. Emerg Infect Dis 2006

Bucket #2: Cost of case: outcome tree



Note: \$ costs in 2000 \$

Source: Zhang et al. Emerg Infect Dis 2006

Bucket #2: Cost of confirmed case

- For each confirmed LD patient
 - \$2,970 direct medical cost
 - \$4,762 indirect medical cost, non-medical cost and productivity loss
- Economic burden of LD in U.S. (2000 \$)
 - 184 million dollars
 - Conservative and underestimated

Note: \$ costs in 2000 \$

Source: Zhang et al. Emerg Infect Dis 2006

Bucket #3: Interventions

- **Vaccination**

- **Control tick hosts**


 - **Population reduction or exclusion**

- **Personal protection**

- **Control ticks**


 - **On hosts or on ground**

Interventions: vaccine: analysis



Source: Meltzer et al. Emerg infect Dis 1999

Results: Cost effectiveness



Source: Meltzer et al. Emerg infect Dis 1999

Conclusions: Vaccine: Cost -effectiveness

- **Public health policy implications**
 - **Value in targeting by risk of LD**
 - **Value in increasing probability of correct early diagnosis and successful treatment**
- **Similar conclusions from:**
 - **Hsia et al. Arthritis & Rheumatism, 2002.**

Interventions: Control hosts




White footed mouse

White tailed deer



Natural hosts and reservoirs of *B. burgdoferi*

Deer Reduction: NJ



Source: Jordan et al, J. Med Entomol, 2007

Personal protection: reduced risk: CT:

- **Protective clothing: 40% (95% C.I.: 30 – 50%)**
- **Tick repellants: 20% (10% - 40%)**
- **Checking for ticks: 0% Not effective**
- **Spraying property: 0% Not effective**

Note: case control: CT. 709 cases

Source: Vazquez et al Emerg Infect Dis 2008

Personal protection: In-yard

- Bathed within 2 hrs: **40%** (95% C.I.: 22% – 77%)
- Tick repellants: **41%** (N/A - 65%)
- Checking for ticks: **45%** (6% - 68%)
- Fencing yard : **46%** (10% – 66%)
- All else (spraying, landscape, etc.): **No effect**

Note: Case control: CT.: 364 cases enrolled
Source: Connally et al. Am J Prevent Med 2009

Self-Medicating applicators: History: Duncan Applicators - 1970s onward



Self-medicating applicators



US005357902A

United States Patent [19]

Norval et al.

[11] **Patent Number:** 5,357,902

[45] **Date of Patent:** Oct. 25, 1994

[54] **SELF-MEDICATING APPLICATOR FOR CONTROLLING PESTS ON ANIMALS**

[75] **Inventors:** R. Andrew Norval; Martin I. Meltzer, both of Gainesville, Fla.; Daniel E. Sonenshine, Virginia Beach, Va.; Michael J. Burrige, Gainesville, Fla.

[73] **Assignees:** Old Dominion University, Norfolk, Va.; University of Florida, Gainesville, Fla.

[21] **Appl. No.:** 102,599

[22] **Filed:** Aug. 5, 1993

[51] **Int. Cl.⁵** A01K 29/00

[52] **U.S. Cl.** 119/157

[58] **Field of Search** 119/156, 157, 158

[56] **References Cited**

U.S. PATENT DOCUMENTS

680,807 8/1901 Pendleton 119/157
988,669 4/1911 Shuler 119/157

FOREIGN PATENT DOCUMENTS

8800079 7/1989 South Africa .

OTHER PUBLICATIONS

Drummond, R. O. et al. (1988) "Effects of Arthropod Pests on Livestock Production" Control of Anthropod Pests of Livestock pp. 1-27.

Sutherst, R. W. et al. (1982) "Tropical legumes of the genus *Stylosanthes* immobilize and kill cattle ticks" Nature 295:320-321.

McCosker, P. J. (1979) "Global Aspects of the Management and Control of Ticks of Veterinary Importance" Recent Advances in Acarology 2:45-53.

Norval, R. A. I. (1990) "The Impact of Pure Infestations of *Rhipicephalus appendiculatus* and *Amblyomma hebraeum* on the Productivity of Cattle and Implications for Tick Control Strategies in Africa" Parassitologia 32:155-163.

Primary Examiner—Gene Mancene

Assistant Examiner—Thomas Price


Attorney, Agent, or Firm—Saliwanchik & Saliwanchik

[57] **ABSTRACT**

The device is a self-medicating applicator that can be



Self-medicating applicators



Source; Norval et. al: Self medicating applicator for controlling pests on animals.
U.S. Patent 5,357,902, Oct 25, 1994.

Impact of applicators: White-tailed deer


| Group | Ticks* / deer | S.E. |
|----------------------|------------------|------|
| Treatment: pesticide | 3.4 | 1.1 |
| Control: mineral oil | 10.8** | 3.0 |

*Ticks: Ixodes scapularis

** $P < 0.0001$

Source: Sonenshine et al Med Vet Entom 1996;10:1490154

Impact of applicators: Nymphs: 5 sites




Source: Brei et al. Vect Borne Zoo Dis, 2009

Potential problem: Alternative hosts

- Mice not primary host for ticks nor primary reservoir for *B. burgdorferi* ss,
- Mice feed 10% all ticks ; 25% *B. burgdorferi*-infected ticks
- Inconspicuous shrews feed 35% all ticks; 55% infected ticks
- May require interventions for multiple species

Source: Dustin et al. Proc R Soc B, 2008

Applicators: What is missing?



In other words: Don't need this . . .



Ixodes scapularis



Source: CDC Public Health Image Library <http://phil.cdc.gov/phil/home.asp>

Need this: Impact on risk of cases



Source: CDC Public Health Image Library <http://phil.cdc.gov/phil/home.asp>

Bucket #4: \$ of interventions

- \$ vaccination - have/ had
- \$ costs of other interventions
 - Appears to be mostly lacking

Bucket #4: Stated support

| | <i>Westport Weston, n (%)</i> | |
|-------------------------|-------------------------------|-----------------------|
| | <i>2002</i> | <i>2004</i> |
| Reduced deer population | 261 (71) | 290 (78) ^a |
| Provide information | 394 (99) | 386 (98) |
| Use pesticides on deer | 288 (80) | 258 (74) ^a |
| Use pesticides | 239 (68) | 256 (70) |

^a $p < 0.05$; ^b $p < 0.01$.

Bucket #4: Beware

- What people say and what they do
 - Often 2 very separate things
- Support of community intervention
 - Depends upon perceptions
 - Can you “see” cases?
- Compliance over time
 - Incredibly big issue
 - “poorly” measured – if at all.

Conclusions: Cost-effectiveness of community based interventions

- **Lack adequate data**
 - **Relationship: tick reduction and cases**
 - **Effectiveness over time**
 - **Compliance over time – usually drops**
- **Costs of interventions**
 - **Sustained – can't stop**
- **Costs of side effects of interventions**

Conclusions: Cost-effectiveness of community based interventions

- **What is needed:**
 - **Field trial(s)**
 - **Large**
 - **Measure impact on cases**
 - **Run for “some time”**
 - **E.g., 3 – 5 years**
 - **Measure changes in community acceptance**
 - **More than 1 site**
 - **Measure – different risks, attitudes, etc.**